Nuclear Energy Board

نویسندگان

  • Fernando Rodriguez
  • Andres Manzano
  • Margarita Garcia
چکیده

Objectives-Firstly, to ascertain whether mortality among workers of the former Spanish Nuclear Energy Board (Junta de Energia Nuclear-JEN) was higher than that for the Spanish population overall; and secondly, if this were so, to ascertain whether this difference was associated with exposure to ionising radiation. Methods-A retrospective follow up of a cohort of 5657 workers was carried out for the period 1954-92. Cohort mortality was compared with that for the Spanish population overall, with standardised mortality ratios (SMRs) adjusted for sex, age, and calendar period. Also, Poisson models were used to analyse mortality from lung cancer in the cohort by level of exposure to ionising radiation. Results-Workers' median and mean cumulative exposures were 4 04 and 11 42 mSv, respectively. Mean annual exposure was 133 mSv. Excess mortality due to bone tumours was found for the cohort as a whole (six deaths observed; SMR 2.95; 95% confidence interval (95% CI) 1-08 to 6.43). Among miners, excess mortality was found for non-malignant respiratory diseases (SMR 2-94; 95% CI 2*27 to 3-75), and for lung cancer bordering on statistical significance (SMR 1 50; 95% CI 0-96 to 2*23; P = 0.055). Relative risks ofdying of lung cancer from ionising radiation in the dose quartiles 2, 3, and 4 versus the lowest dose quartile, were 1*00, 164, and 0*94, respectively. Conclusions-Excess mortality from lung cancer was found among JEN miners. Nevertheless, no clear relation was found between mortality from lung cancer and level of exposure to ionising radiation in the JEN cohort. Continued follow up of the cohort is required to confirm excess mortality from bone tumours. (Occup Environ Med 1997;54:202-208)

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Membrane Assisted Liquid Extraction of Actinides and Remediation of Nuclear Waste: A Review

Membrane assisted liquid extraction(MALE) technologies are gaining an important role as an extraction /separation technique for actinides and are being deployed as a  promising tool for remediation of nuclear waste generated in the reprocessing plant and other radioactive wastes containing a trace level of radionuclides. The present contribution outlines the classification of membrane assisted ...

متن کامل

The Defense Nuclear Facilities Safety Board's first decade.

Concern over the safety of the United States' defense nuclear reactors in the late 1980s led to congressional creation of an independent oversight board. The Defense Nuclear Facility Safeties Board (DNFSB) is responsible for overseeing safety issues at the U.S. Department of Energy's nuclear facilities and issuing recommendations on operations and safety at these facilities, which include South...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Preparation of [111In]-Bleomycin radiopharmaceutical [Persian]

In this study, the preparation of 111In-Bleomycin complex was optimized for temperature, time, concentration and pH during several experiments. The results showed that by the addition of bleomycin to 111In-InCl3 sample (dried under flow of N2) and heating the mixture up to 90-100°C the radiopharmaceutical can be obtained in 99.5% yield and a specific activity of 1.745 Ci/mmol. The final s...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2005